TrialHeadache2020

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.

Janet H Ford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.